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Abstract 
The aim of the present study was to formulate and evaluate oral thin films of zolpidem tartarate. 
Zolpidem tartarateis used to treat insomnia. It affects chemicals in your brain that may become 
unbalanced and cause sleep problems (insomnia). Zolpidem tartarate oral thin films were prepared by 
using solvent casting method. In this method, water soluble polymer is completely dissolved in to form 
uniform clear viscous solution other ingredients including API are dissolved in a small portion of 
aqueous solvent by using a high shear processor. This viscous solution is degassed under the vacuum to 
remove the air bubbles. This bubble free solution is poured into a glass mold and kept in oven at 40 
º-50ºC. Oral disintegrating films are prepared using three grades of polymers HPMC E5, GUAR GUM 
and SODIUM ALGINATE Compatibility of Zolpidem tartarate with polymers was confirmed by FT-IR 
studies. All the formulations were evaluated for their physical appearance, average weight and 
thickness, folding endurance, disintegration time, tensile strength, percentage elongation, drug content, 
content uniformity and in vitro drug dissolution studies. From the result, it was concluded that the fast 
dissolving films of Zolpidem tartarate can be made by solvent casting technique with enhanced 
dissolution rate and taste masking by using suitable combination of sweeteners, flavors and citric acid. 
The final composition optimized was drug to Guar Gum ratio of 1:1, plasticizer concentration of 15% 
w/w of polymer. The film had acceptable physical properties, assay and uniformity values and in vitro 
dissolution within 2 minutes. 
Keywords 
oral thin films, Zolpidem tartarate, solvent casting, placebo films, guar gum, sodium alginate, HPMC 
E5 
 
1. Introduction 
Fast-dissolving drug-delivery systems were first developed in the late 1970s as an alternative to tablets, 
capsules, and syrups for pediatric and geriatric patients who experience difficulties swallowing 
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traditional oral solid-dosage forms. The novel technology of oral fast-dispersing dosage forms is known 
as fast dissolve, rapid dissolve, rapid melt and quick disintegrating tablets. However, the function and 
concept of all these dosage forms are similar. By definition, a solid dosage form that dissolves or 
disintegrates quickly in the oral cavity, resulting in solution or suspension without the need for the 
administration of water, is known as an oral fast-dispersing dosage form. 
Oral films, also called oral wafers in the related literature, are a group of flat films which are 
administered into the oral cavity. Dissolvable Oral Thin Films (OTFs) or Oral Strip (OS) evolved over 
the past few years from the confection and oral care markets in the form of breath strips and became a 
novel and widely accepted form by consumers for delivering Vitamins and personal care products. 
Many pharmaceutical companies have directed their research activity in reformulating existing drugs 
into new dosage forms. One such relatively new dosage form is the oral strip, a thin film that is 
prepared using hydrophilic polymers that rapidly dissolves on the tongue or buccal cavity. Developing 
formulations for children has been a challenging task. Amongst other factors, palatability of 
formulations of pediatric oral medications is one of the most Significant factors influencing compliance 
to therapeutic regimens. 
Many pediatric and geriatric patients are unwilling to take these solid preparations due to fear of 
choking. Although oral disintegrating tablets have an advantage of administration without choking and 
fast disintegration; the disintegrated materials contained in them are insoluble and remain same until 
swallowing. In such cases formulation of fast dissolving film will be advantageous. So, in the present 
investigation we have prepared oral thin films of zolpidem tartarate. Oral thin films were prepared by 
using solvent casting, semisolid casting, hot melt extrusion, solid dispersion extrusion and rolling 
methods. 
Zolpidem tartarate is a sedative, also called a hypnotic. Zolpidem tartarateis used to treat insomnia. It 
affects chemicals in your brain that may become unbalanced and cause sleep problems (insomnia). 
Zolpidem tartarate oral thin films were prepared by using solvent casting method. In this method, water 
soluble polymer is completely dissolved in to form uniform clear viscous solution other ingredients 
including API are dissolved in a small portion of aqueous solvent by using a high shear processor. This 
viscous solution is degassed under the vacuum to remove the air bubbles. This bubble free solution is 
poured into a glass mold and kept in oven at 40º-50ºC. 
 
2. Materials and Methods 
Materials: Zolpidem Tartarate was obtained as a gift sample from EMCO industries, Hyderabad. 
HPMCE5, guar gum, sodium alginate are obtained from Loba chemicals, India. Glycerol, PEG 400, 
mannitol are obtained from Merck, India. All the solvents use was analytical grade. 
2.1 Methods 
2.1.1 Construction of Calibration Curve 
Accurately weighed amount of 100 mg of drug was dissolved in ethanol in 100 mL volumetric flask 
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and the volume was made up to 100 mL. This indicates the standard stock solution-1 mg/ml in ethanol. 
From this stock solution 10 mL of solution was withdrawn and poured in to 100 mL volumetric flask 
and the volume was made up with phosphate buffer Ph 6.8, this indicates the working stock-100 µg/ml. 
from this, working stock corresponding dilutions were made to get concentrations of 2, 4, 6, 8 and 10 
µg/ml and analyzed at 240 nm spectrophotometrically metrically against the reagent blank at 240 nm 
and a calibration curve was constructed. 
2.1.2 Drug Polymer Compatibility Studies 
The infrared spectra of drug, polymers, physical mixture of drug and polymers were recorded at a 
scanning range of 400-4000 cm-1 using FTIR spectrometer. 
2.2 Formulation Development 
2.2.1 Placebo Formulations 
Placebo formulations were prepared by using solvent casting technique. The film forming polymers 
HPMCE5, GUAR GUM and SODIUM ALGINATE were accurately weighed and dispersed in 10 ml of 
distilled water each and then soaked for 4 hours. To these polymer solutions, Mannitol was added with 
continuous stirring on a magnetic stirrer. The resulting bubble free solution was poured on to a glass 
plate and was dried at 50C in hot air oven for 24 hr. The placebo films formed were carefully removed 
from glass plate and evaluated for drying time, average weight, thickness, tensile strength, folding 
endurance and in vitro disintegration time. The placebo film formulations are given in Table 1 and 
Table 2. 
2.2.2 Drug Loaded Formulations 
The composition for the drug loaded films is given in Table 3. The procedure followed was similar to 
the placebo formulations. The Zolpidem Tartarate was added to the polymer solution and sonicated for 
15 minutes till the drug was completely dissolved. The drug loaded films were evaluated for average 
weight, thickness, tensile strength, folding endurance, in vitro disintegration time and in vitro 
dissolution studies. 
 
Table 1. Composition of Placebo Formulations with Glycerol as Plasticizer 
Ingredients 5f1 5f2 5f3 5f4 15f1 15f2 15f3 15f4 Pf1 Pf2 Pf3 
HPMC E5 (mg) 62.5 125 187.5 250 - - - - - - - 
GUAR GUM (mg) - - - - 62.5 125 187.5 250 - - - 
SODIUM 
ALGINATE (mg) 
- - - - - - - - 125 187.5 250 
GLYCEROL (mg) 9.38 18 28.1 37.5 9.38 18.7 28.1 37.5 18.7 28.1 37.5 
MANNITOL (mg) 100 100 100 100 100 100 100 100 100 100 100 
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DISTILLED 
WATER (ml) 
10 10 10 10 10 10 10 10 10 10 10 
 
Table 2. Composition of Placebo Formulations with PEG 400 as Plasticizer 
INGREDIENTS 5f5 5f6 5f7 5f8 15f5 15f6 15f7 15f8 Pf4 Pf5 Pf6 
HPMC E5 (mg) 62.5 125 187.5 250 - - - - - - - 
GUAR GUM (mg) - - - - 62.5 125 187.5 250 - - - 
SODIUM 
ALGINATE (mg) 
- - - - - - - - 125 187.5 250 
PEG 400 (mg) 9.38 18 28.1 37.5 9.38 18.7 28.1 37.5 18.7 28.1 37.5 
MANNITOL (mg) 100 100 100 100 100 100 100 100 100 100 100 
DISTILLED WATER 
(ml) 
10 10 10 10 10 10 10 10 10 10 10 
 
Table 3. Composition of Drug Loaded Zolpidem Tartarate Films 
 HPMC E5 GUAR GUM 
Ingredients  F1 F2 F3 F4 F5 F6 F7 
Drug (mg) 62.5 62.5 62.5 62.5 62.5 62.5 62.5 
Polymer (mg) 125 187.5 250 62.5 125 187.5 250 
Glycerol (mg) 18.7 28.1 37.5 9.38 18.7 28.1 37.5 
Mannitol (mg) 100 100 100 100 100 100 100 
Flavour 5% 5% 5% 5% 5% 5% 5% 
Distilled Water(ml) 10 10 10 10 10 10 10 
 
3. Evaluation of the Oral Dissolving Films 
3.1 Average Weight Measurements 
The weight of the films was determined by Analytical Balance. One centimeter square was cut at five 
different places in the casted film. The weight of each film was taken and the average weight was 
calculated. Uniformity in weight of the films indicates accuracy of dose of the oral films. 
3.2 Thickness 
Uniformity in the thickness of the film was related in accuracy of dose of the ODFs. At different 
locations of the strip the thickness was measured using Vernier Calipers Micrometer. Folding 
Endurance: Folding endurance indicates mechanical strength of the oral films and was determined by 
folding the strip repeatedly at the same place till it breaks. The number of times the film was folded 
without breaking and it was computed as the folding endurance value. 
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3.3 Tensile Strength 
Tensile strength indicates mechanical strength of the oral films. It indicates maximum stress required to 
break the strip when applied at a point. It was determined using Texture Analyzer Stable Micro system. 
3.4 Percentage Elongation 
Percentage elongation of the strip was determined using Texture Analyzer Stable Micro system. The 
strip was taken and force was gradually applied till the film elongates and finally breaks. The readings 
were taken from the instrument.  
3.5 Assay and Content Uniformity 
Films of 2×1 cm2 were taken and dissolved in pH 6.8 Phosphate buffer and made up to 100 ml in a 
volumetric flask. Then 1mL was withdrawn from the solution and diluted to 10 mL. The absorbance of 
the solution was measured spectrophotometrically at 240 nm. The assay was calculated by this method. 
Limit of content uniformity is 85-115%.  
3.6 Disintegration Time 
The film equivalent to one dose (2×1 cm2) was placed in a glass petridish containing 10 ml of pH 6.8 
phosphate buffer. The time required for the film to break was noted as disintegration time.  
3.7 In Vitro Dissolution Studies 
The in-vitro dissolution studies were conducted using simulated saliva (500 mL). The dissolution 
studies were carried out using USP dissolution apparatus I (Electrolab, Mumbai, India) at 37±0.5 °C 
and at 50 rpm using specified dissolution media. Each film with dimension (2x1 cm2) was placed on a 
stainless-steel wire mesh. The film sample placed on the sieve was submerged into dissolution media. 
Samples were withdrawn at 0, 2, 5, 10, 15 and 30 min. time intervals and filtered through wattmann 
filter paper and were analyzed spectrophotometrically at 240 nm. To maintain the volume, an equal 
volume of fresh dissolution medium maintained at same temperature was added after withdrawing 
samples. The absorbance values were converted to concentration using standard calibration curve 
previously obtained by experiment. 
 
4. Kinetic Modelling 
4.1 Release Kinetic Models 
Model dependent methods are based on different mathematical functions, which describe the 
dissolution profile. Once a suitable function has been selected, the dissolution profiles can easily be 
evaluated depending on the derived model parameters. The model dependent approaches includes zero 
order, first order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas, Baker-Lonsdale, Weibull, Hopfenberg, 
Gompertz, Non-conventional order 1, Non-conventional order 2, Reciprocal powered time and 
regression models. Among them tried four models to fit the data with zero order, first order, Higuchi, 
and Korsmeyer-Peppas models. 
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4.2 Zero-Order Model 
Drug dissolution from dosage forms that do not disaggregate and release the drug slowly can be 
represented by the equation:  
T
T kQQ 00   Rearrangement of equation yields: 
T
T kQQ 00 
 
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the solution 
(most of the times, Q0=0) and K0 is the zero order release constant expressed in units of 
concentration/time. 
Plotted the cumulative amount of drug released versus time. This relationship can be used to describe 
the drug dissolution of several types of modified release pharmaceutical dosage forms as in the case of 
some transdermal systems, as well as matrix tablets with low soluble drugs, coated forms, osmotic 
systems, etc. 
4.3 First Order Model 
The application of this model to drug dissolution studies was first proposed by Gibaldi and Feldman 
(1967) and later by Wagner (1969). This model has been also used to describe absorption and/or 
elimination of some drugs, although it is difficult to conceptualize this mechanism on a theoretical 
basis. The release of the drug which follows first order kinetics can be expressed by the equation:  
C
t
C k
d
d   
Where K is first order rate constant expressed in units of time-1.  
Equation can be expressed in log form as: 
303.2
loglog 0 t
kCC 
 
Where C0 is the initial concentration of drug, K is the first order rate constant, and t is the time. The 
data obtained are plotted as log cumulative percentage of drug remaining vs. time which would yield a 
straight line with a slope of -K/2.303. 
4.4 Higuchi Model 
This model is used to study the release of water soluble and poorly soluble drugs incorporated in 
semi-solid and/or solid matrices. Mathematical expressions are obtained for drug particles dispersed in 
a uniform matrix behaving as the diffusion media. To study the dissolution from a planar system 
having a homogeneous matrix, the relation obtained is as following: 
tCCCDQf SSt )2(   
Where Qis the amount of drug released in time tper unit area, Cis the drug initial concentration, Cis the 
drug S solubility in the matrix media and Dis the diffusivity of the drug molecules (diffusion constant) 
in the matrix substance. This relation was first proposed by Higuchi (1961, 1963) to describe the 
dissolution of drugs in suspension from ointments bases, but is clearly in accordance with other types 
of dissolution from other pharmaceutical dosage forms. 
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In a general way it is possible to resume the Higuchi model to the following expression (generally 
known as the simplified Higuchi model): 
2
1
tKf Ht   
Where KH is the Higuchi dissolution constant treated sometimes in a different manner by different 
authors and theories. Higuchi describes drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms, as in the case of some trans dermal systems 
and matrix tablets with water soluble drugs. 
 
5. Results and Discussion 
5.1 Preformulation Studies 
Calibration curve of Zolpidem tartarate: The absorbance values for different concentration of 
Zolpidem tartarate standard solutions are recorded in Table 4 and shown in Figure 1. 
 
Table 4. Calibration Curve of Zolpidem Tartarate in Phosphate Buffer pH 6.8 
Concentration (µg/ml) Absorbance at 240 nm 
0 0 
2 0.172 
4 0.325 
6 0.501 
8 0.683 
10 0.829 
 
 
Figure 1. Calibration Curve of Zolpidem Tartarate in Phosphate Buffer pH 6.8 
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Figure 1 indicates the UV-spectrometric method is linear in the range of 2 to 10 ug/ml and obtained the 
R2 value as 0.9993. From the equation, we can calculate the concentration of the samples measured. 
5.2 Drug-Excipients Compatibility Studies 
FTIR spectrum of the drug and drug in the presence of the polymers was recorded and the 
characteristic peaks of the drug identified in the physical mixture indicating the absence of the 
interaction of the drug with polymers. As shown in Table 5, the characteristic peaks of the drug for the 
bonds occur at similar wave numbers with same intensity in the physical mixture and pure drug. 
 
Table 5. FTIR Interpretation of Zolpidem Tartarate and Guar Gum 
Functional groups Zolpidem tartarate Guar Gum Formulation 
O-H Stretching 3738 cm-1 3755 cm-1 3744 cm-1 
N-H stretching 3398 cm-1 - 3393 cm-1 
C=O stretching 1656 cm-1 - 1633 cm-1 
C-H stretching 2900 cm-1 2910 cm-1 2939 cm-1 
C=N Stretching 1508 cm-1 - 1509 cm-1 
 
 
Figure 2. FTIR of Zolpidem Tartarate 
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Figure 3. FTIR of Formulation 
 
The characteristic peaks of pure drug, GUAR GUM, physical mixture were illustrated in Figures 2, 3. 
The O-H stretching, N-H stretching, C=O stretching, C-H stretching and heterocyclic C=N stretching 
of zolpidem tartarate was observed at 3738 cm-1, 3398 cm-1, 1656 cm-1, 2900 cm-1 and 1508 cm-1 
respectively. The O-H stretching, N-H stretching, C=O stretching, C-H stretching and heterocyclic 
C=N stretching of the formulation was observed at 3744 cm-1, 3393 cm-1, 1633 cm-1, 2939 cm-1 and 
1509 cm-1. From this it can be concluded that there is no change in the O-H stretching, N-H stretching, 
C=O stretching and C=N stretching of the drug and the formulation. There is a slight but not significant 
change in the C-H stretching of the formulation than the drug. So, in the formulation, no considerable 
changes were observed in the peaks and it can be concluded that there are no interactions with the drug 
and the peak height, intensity, position of peak of drug is similar without variations indicating that drug 
and polymers are compatible. This interaction study revealed that no toxic effects can be found in the 
formulation. 
 
6. Evaluation of Oral Dissolving Films 
6.1 Placebo Films 
The plasticizers used were PEG 400 and Glycerol. Films made by PEG 400 were sticky and they are 
difficult to remove from the plate. Plasticity and tackiness is also poor for these films. So, glycerol was 
selected as an optimized plasticizer. Concentration of glycerol less than 15% w/w was not enough to 
plasticize the films and therefore 15% w/w of the glycerol was selected as an optimized concentration. 
The drying time for Sodium Alginate based films were unacceptably long (>24 hours). Also these films 
were much inferior to HPMC based films in terms disintegration time and thickness values. The HPMC 
E5 and guar gum films showed acceptable values for the evaluated parameters and were selected for 
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the drug loading studies. Among the films made of HPMC E5 5f1 (1:1) formulation showed poor 
results. So, it is not selected for drug loading studies. 
 
Table 6. Evaluation Parameters of HPMC E5, GUAR GUM and SODIUM ALGINATE 
Evaluation parameters 
HPMC E 5 GUAR GUM 
5f1 5f2 5f3 5f4 15f1 15f2 15f3 15f4 
Drying time (hrs) 16-24 16-24 16-24 16-24 16-24 16-24 16-24 16-24 
in vitro Disintegration 
time (secs) 
22±5 52±2 59±3 63±2 47±3 58±1 66±2 77±2 
Folding endurance 28±4 119±1 129±2 134±1 110±3 122±3 133±1 140±1 
Average weight (mg) 4±3 10±4 14±3 18±2 8.5±3 14±3 17±2 20±1 
Thickness (mm) 
0.09±0.2 0.07±0.1
0.1± 
0.01 
0.121±0.02 0.06±0.01 0.105±0.01 0.12±0.2 0.14±0.1
Tensile strength 
(N/cm2) 
0.02±0.4 0.99±0.5 1.65±0.1 1.99±0.02 1.74±0.03 1.99±0.1 2.28±0.2 2.78±0.2
 
Evaluation parameters SODIUM ALGINATE 
 Pf1 Pf2 Pf3 
Drying time(hrs) ˃24 ˃24 ˃24 
in vitro Disintegration time (secs) 130±2 152±1 179±3 
Folding endurance 162±4 184±2 191±5 
Average weight(mg) 48±4 61±3 70±2 
Thickness (mm) 0.182±0.02 0.206±0.01 0.311±0.02 
Tensile strength (N/cm2) 3.78±0.01 4.03±0.03 4.97±0.02 
 
7. Drug Loaded Films 
7.1 Physical Appearance of the Films 
The pictures of ODFs of all the formulations are shown in Figure 4. The pictures A, B and C indicates 
HPMC E 5 containing films, it was observed that the films were thin with lower peal ability, though 
they were transparent. The viscosity of the film former was 5 cps (Rowe et al., 2006) which was lower 
resulting in thin films. The pictures E, F, G and H indicate Guar Gum containing films. It was observed 
that the films with Guar Gum were transparent with good peal ability, flexibility and with smooth 
surface when compared to HPMC E 5 containing films. This is because the viscosity of the film former 
being high (Guar Gum) (Rowe et al., 2006). The results were comparable with reports of Kaur and Bala 
(2012) where the effect of physical appearance of the films were studied in the presence of Guar Gum 
containing films and with Vijayasri (2012) where the promising polymer Guar Gum is showing good 
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physical characteristics. 
 
 
 A B C 
 
  E F G 
 
 
Figure 4. Physical Appearance of Drug Loaded Formulations 
 
Table 7. Comparative Results of Evaluation Parameters of ODF Formulations 
Formulation 
code 
Average 
weight 
(mg) 
Thickness 
(mm) 
Folding 
endurance
invitro 
disintegration 
time (secs) 
Tensile 
strength 
(N/cm2) 
% 
elongation 
Drug 
content 
(mg) 
Content 
uniformity
(%) 
F1 16.5±0.3 0.082±0.01 119±1 52±1 1.03±0.05 25.44±0.68 3.52 103-105 
F2 18±0.4 0.109±0.02 130.3±9 60±2 1.87±0.01 49.5±0.62 3.48 89-101 
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F3 19.9±0.8 0.126±0.01 136.3±3 65±2 2.23±0.04 65.5±0.50 3.39 83-91 
F4 14.7±0.7 0.081±0.02 112±3 49±2 1.88±0.02 25.62±0.82 3.57 100-104 
F5 19±2.6 0.113±0.01 134±2 58±1 2.03±0.07 38.94±0.83 3.60 85-93 
F6 21.4±0.4 0.134±0.05 145.3±2 69±2 2.43±0.02 69.2±0.36 3.46 85-87 
F7 22±2 0.157±0.02 150.6±1 78±1 3.02±0.01 71.6±0.23 3.35 90-98 
 
7.2 In Vitro Dissolution Studies of ODFs 
The in vitro drug dissolution study of Zolpidem tartarate from all the formulations was performed by 
using USP Type I basket apparatus, using 500 mL of phosphate buffer pH 6.8. 
Drug release from formulations F1, F2 and F3: F1, F2 and F3 formulations are formulated using 
HPMC E5 as film former at 1:2, 1:3 and 1:4 ratios of drug to polymer respectively. Percent drug release 
profiles from formulations F1, F2 and F3 are shown in Figure 5 and the Table 8. As the ODFs are thin 
films with more surface area, they get wet quickly. Within 15 minutes 99.6% of the drug was released 
from F1 formulation, 96.2% of the drug from F2 formulation and 94.9 from F3 formulation. As the film 
former concentration was increased the rate of drug release was decreased because of the decreased rate 
of erosion of the films.  
 
Table 8. Drug Release Profiles of Formulations with Film Former HPMC E5-F1, F2 and F3 
Time (mins) F1 F2 F3 
0 0 0 0 
2 88±0.01 81.5±0.01 76.4±0.05 
5 92±0.11 89±0.03 84.6±0.12 
10 97.28±0.20 94.6±0.05 89.6±0.15 
15 99.6±0.02 96.2±0.11 94.9±0.20 
30 100±0.10 97±0.12 95.8±0.02 
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Figure 5. Comparative Percent Drug Release Profiles from Formulations F1, F2 and F3 
 
Drug release from formulations F4, F5, F6 and F7: F4, F5, F6 and F7 formulations are formulated 
using Guar Gum as film former at 1:1, 1:2, 1:3 and 1:4 ratios of drug to polymer respectively. From the 
Figure 6 and the Table 9, it can be observed that the F4 formulation showed faster release of the drug 
about 99.98 within 15 minutes than F5, F6 and F7, where the percent drug release was 98.4, 94.7 and 
92.9 respectively. As the film former concentration was increased the rate of drug release was 
decreased because the erosion of the films might have probably delayed.  
 
Table 9. Drug Release Profiles of Formulations with Former Guar Gum-F4, F5, F6 and F7 
Time (mins) F4 F5 F6 F7 
0 0 0 0 0 
2 89.2±0.10 85±0.05 80.9±0.05 76±0.05 
5 94±0.06 90±0.08 88.91±0.01 84±0.08 
10 98.81±0.11 94±0.10 92.7±0.06 86.8±0.11 
15 99.98±0.05 98.4±0.11 94.7±0.14 92.9±0.10 
30 101.81±0.11 99.6±0.12 95±0.11 93±0.13 
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Figure 6. Comparative Drug Release Profiles from Formulations F4, F5, F6 and F7 
 
 
Figure 7. Comparison of Disintegration Time and Drug Release in 2 Minutes of ODFs 
 
There is a marginal but not significant difference in dissolution between different compositions. The 
dissolution profile (% Drug release in 2 mins) Vs disintegration time (seconds) is shown in Figure 7. 
 
 
 
 
 
 
 
www.scholink.org/ojs/index.php/mshp                   Medical Science & Healthcare Practice              Vol. 1, No. 1, 2017 
40 
Published by SCHOLINK INC. 
7.3 Release Kinetics 
 
Table 10. Release Rate Kinetics 
Formulation Code Zero Order Equation First Order Equation Higuchi Equation 
 K R2 K R2 N R2 
F1 0.8955 0.9294 0.1385 0.9573 81.266 0.9916
F2 1.087 0.8032 0.0818 0.8756 74.219 0.9631
F3 1.3398 0.8341 0.0721 0.8453 66.936 0.985 
F4 0.8192 0.9642 0.2197 0.9902 83.45 0.9951
F5 0.9878 0.8776 0.0968 0.9013 77.667 0.9483
F6 0.9813 0.7413 0.0708 0.8469 74.698 0.9267
F7 1.1827 0.7687 0.0617 0.8014 97.816 0.9199
 
After undergoing the release models for all the formulations the in vitro drug release of the optimized 
formulations F4 and F5 were best explained by first order, as the plots showed the highest linearity with 
determination coefficient R2=0.9902 and R2=0.9013 respectively. The rate laws predicted by the 
different mechanisms of dissolution both alone and in combination, have been discussed by Higuchi. 
The equation in resemblance to the other rate law equations, predicts a first order dependence on the 
concentration gradient between the static liquid layer next to the solid surface and the bulk liquid. 
Noyes and Whitney explained their dissolution data using a concept similar to that used for the 
diffusion model. The data generated for all the formulations not fitted well to zero order kinetics and 
this model was not suitable to explain the rate kinetics for oral fast dissolving film formulations. The 
data was fitted with Higuchi equation which yielded almost linear plots with their high determination 
co-efficient R2 ranging from 0.926 to 0.991 for all formulations indicating that the mechanism of drug 
release was diffusion.  
Summary and Conclusion: The main objective of the study was to formulate Zolpidem tartarate films 
as an alternative to Zolpidem sublingual tablet (INTERMEZZO) and evaluate the films. ODFs are 
prepared using three grades of polymers HPMC E5, GUAR GUM and SODIUM ALGINATE 
Compatibility of Zolpidem tartarate with polymers was confirmed by FT-IR studies. All the 
formulations were evaluated for their physical appearance, average weight, and thickness, folding 
endurance, disintegration time, tensile strength, percentage elongation, drug content, content uniformity 
and in vitro drug dissolution studies. Uniformity in the weights, thickness of the films indicated 
accuracy of dose in all formulations. F4 formulation showed least thickness of 0.081±0.02 mm. tensile 
strength and folding endurance was increased with increase in the concentration of the polymer due to 
the increase in the elasticity nature of the polymer. Percentage drug content studies showed that the 
drug is uniformly distributed within the films. All the films acceptable content uniformity range as per 
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USP. Disintegration and in vitro dissolution studies proved that the films instantly get wet because of 
great surface area and the films disintegrate and release the drug by the mechanism of film forming 
polymer erosion. From the drug dissolution characteristics, formulations formulated by HPMC E 5 
have shown faster dissolution than GUAR GUM formulations (F5, F6 and F7). F4 formulation 
exhibited required Disintegration time of 49±2 seconds, acceptable content uniformity, and Tensile 
strength of 1.88±0.02 N/cm2 and in vitro dissolution of 99.98% within 15 minutes. From the result, it 
was concluded that the fast dissolving films of Zolpidem tartarate can be made by solvent casting 
technique with enhanced dissolution rate and taste masking by using suitable combination of 
sweeteners, flavors and citric acid. The final composition optimized was drug to Guar Gum ratio of 1:1, 
plasticizer concentration of 15% w/w of polymer. The film had acceptable physical properties, assay 
and uniformity values and in vitro dissolution within 2 minutes. 
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